We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$710M
AUM Growth
+$164M
Cap. Flow
+$64.1M
Cap. Flow %
9.04%
Top 10 Hldgs %
36.24%
Holding
113
New
11
Increased
54
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$15.7M
2
INSP icon
Inspire Medical Systems
INSP
+$12.4M
3
AMGN icon
Amgen
AMGN
+$11.3M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.7M
5
QGEN icon
Qiagen
QGEN
+$10M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13.8M
2
IMGN
Immunogen Inc
IMGN
+$11.4M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$8.68M
4
CRL icon
Charles River Laboratories
CRL
+$8.65M
5
ZBH icon
Zimmer Biomet
ZBH
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
2 Industrials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
51
DELISTED
Nuvalent
NUVL
$4.41M 0.62%
+59,867
New +$3.7M
MRUS
52
DELISTED
Merus
MRUS
$4.34M 0.61%
157,817
+27,082
+21% +$632K
CRNX icon
53
Crinetics Pharmaceuticals
CRNX
$8.96B
$4.29M 0.6%
120,652
+20,652
+21% +$633K
ESPR
54
DELISTED
Esperion Therapeutics
ESPR
$4.26M 0.6%
1,425,204
-571,867
-29% -$742K
BBIO icon
55
BridgeBio Pharma
BBIO
$16.4B
$4.07M 0.57%
100,734
+734
+0.7% +$22K
SLN
56
Silence Therapeutics
SLN
$641M
$4.05M 0.57%
232,942
+40,063
+21% +$450K
QTRX icon
57
Quanterix
QTRX
$139M
$4M 0.56%
146,366
+69,279
+90% +$1.63M
LYRA
58
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.96M 0.56%
15,098
+2,597
+21% +$470K
NEO icon
59
NeoGenomics
NEO
$2.11B
$3.85M 0.54%
237,762
-8,050
-3% -$132K
DVAX
60
DELISTED
Dynavax Technologies
DVAX
$3.55M 0.5%
+253,947
New +$3.53M
TGTX icon
61
TG Therapeutics
TGTX
$7.58B
$3.51M 0.49%
205,317
-4,002
-2% -$46.5K
SUPN icon
62
Supernus Pharmaceuticals
SUPN
$2.78B
$3.46M 0.49%
119,417
-18,755
-14% -$497K
APLT
63
DELISTED
Applied Therapeutics
APLT
$3.41M 0.48%
1,019,156
-730,844
-42% -$1.82M
NAMS icon
64
NewAmsterdam Pharma
NAMS
$3.33B
$3.36M 0.47%
300,750
+51,726
+21% +$474K
AKYA
65
DELISTED
Akoya BioSciences
AKYA
$3.29M 0.46%
674,787
+149,164
+28% +$620K
CRSP icon
66
PUT
CRISPR Therapeutics
CRSP
$5.22B
$3.13M 0.44%
+50,000
New +$2.76M
SIBN icon
67
SI-BONE Inc
SIBN
$852M
$3.06M 0.43%
145,575
-9,471
-6% -$175K
URGN icon
68
UroGen Pharma
URGN
$2.39B
$2.63M 0.37%
175,500
+30,189
+21% +$392K
LBPH
69
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$2.59M 0.37%
429,892
+73,935
+21% +$368K
ETNB
70
DELISTED
89bio
ETNB
$2.45M 0.35%
219,448
-144,105
-40% -$1.32M
ABOS icon
71
Acumen Pharmaceuticals
ABOS
$181M
$2.32M 0.33%
603,497
+103,683
+21% +$308K
SLGC
72
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.25M 0.32%
+890,099
New +$2.07M
YARW
73
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$1.62M 0.23%
+13,929
New +$2.17M
GPCR icon
74
Structure Therapeutics
GPCR
$3.83B
$1.58M 0.22%
38,678
+8,678
+29% +$497K
IRWD icon
75
Ironwood Pharmaceuticals
IRWD
$714M
$1.38M 0.19%
120,652
+20,652
+21% +$204K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Parkman Healthcare Partners held 113 positions worth $710M, up 30% from $546M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners deployed $64.1M of net new capital in Q4 2023, opening 11 new positions and adding to 54 existing holdings. Its largest new stake was Abbott: 156,727 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Becton Dickinson, an estimated $7.52M trimmed.

  • Parkman Healthcare Partners's largest Q4 2023 buy was Abbott: 156,727 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Inspire Medical Systems in Q4 2023, an estimated $12.4M increase.
  • Parkman Healthcare Partners's biggest Q4 2023 reduction was Becton Dickinson, cutting an estimated $7.52M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q4 2023, selling an estimated $13.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $710M portfolio in Q4 2023.
  • Parkman Healthcare Partners opened 11 new positions and closed 24 in Q4 2023.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $710M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.